Eli Lilly & Co. (LLY)

109.81
2.01 1.80
NYSE : Health Technology
Prev Close 111.82
Open 112.36
Day Low/High 109.74 / 112.65
52 Wk Low/High 73.69 / 116.61
Volume 5.39M
Avg Volume 4.02M
Exchange NYSE
Shares Outstanding 1.06B
Market Cap 119.92B
EPS -0.20
P/E Ratio 240.85
Div & Yield 2.25 (1.97%)

Latest News

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AES, ALIM, APPS, EXAS, INVH, LBRDA, LBRDK, LLY, TLK Downgrades: CTT, DRH, HA, MTDR, ORIT, RNG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly's excellent earnings weren't excellent enough.

Nasdaq Gains for First Day in Three as U.S. Voters Head to the Polls

Nasdaq Gains for First Day in Three as U.S. Voters Head to the Polls

The Dow and S&P 500 are posting modest gains on Tuesday as voters head to the polls for the U.S. midterm elections.

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Eli Lilly Tops Q3 Earnings Estimate, Lifts 2018 Outlook as Diabetes Sales Rise

Eli Lilly Tops Q3 Earnings Estimate, Lifts 2018 Outlook as Diabetes Sales Rise

Eli Lilly posted stronger-than-expected third quarter earnings Tuesday, and boosted its 2018 profit guidance for the second consecutive time this year as its diabetes drug franchise continues to add to the group's bottom line.

Wall Street Continues to See Opportunity in Eli Lilly

Wall Street Continues to See Opportunity in Eli Lilly

LLY's stock slide after earnings might present a buying opportunity.

2 Groups to Watch as the Midterm Election Unfolds: Cannabis and Drug Stocks

2 Groups to Watch as the Midterm Election Unfolds: Cannabis and Drug Stocks

A bunch of pot stocks are in play on Tuesday -- for a reason.

Eli Lilly Offers Healthy Outlook to Kick Off November

Eli Lilly Offers Healthy Outlook to Kick Off November

The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.

Eli Lilly Could Hit New Highs, but Market Weakness Could Mute Gains

Eli Lilly Could Hit New Highs, but Market Weakness Could Mute Gains

It shouldn't hurt that the drugmaker beat third-quarter estimates and raised its profit guidance for all of 2018.

Midterms, Amazon, Toyota and Under Armour - 5 Things You Must Know

Midterms, Amazon, Toyota and Under Armour - 5 Things You Must Know

U.S. stock futures are lower on Tuesday as Wall Street's focus turns to the midterm elections; Eli Lilly and CVS Health report earnings; Amazon reportedly to split its second headquarters in two locations; Under Armour says will accelerate a culture change following a report about workplace misconduct.

Stocks Drift Lower Ahead of US Midterm Elections; Dollar, Yields Edge Higher

Stocks Drift Lower Ahead of US Midterm Elections; Dollar, Yields Edge Higher

Global stocks steadied Tuesday, even as interest rates crept higher and the dollar regained its composure against rival currencies, with investors unambiguously focused on the outcome of midterm elections later today that could either stall or extend the longest equity bull market in history.

Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance

Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance

- Third-quarter 2018 revenue increased 7 percent, driven primarily by increased demand for new medicines, while operating expenses increased 1 percent.

Jim Cramer: Keep an Eye on the Insiders Who Are Buying

Jim Cramer: Keep an Eye on the Insiders Who Are Buying

Insiders buy for only one reason -- to make money.

Trulicity® (dulaglutide) Demonstrates Superiority In Reduction Of Cardiovascular Events For Broad Range Of People With Type 2 Diabetes

Trulicity® (dulaglutide) Demonstrates Superiority In Reduction Of Cardiovascular Events For Broad Range Of People With Type 2 Diabetes

Only 31 percent of REWIND trial participants had established CV disease

Initial Results From EMPRISE Real-world Evidence Study Show Jardiance® Was Associated With Reduced Risk For Hospitalization For Heart Failure Compared With DPP-4 Inhibitors In People With Type 2 Diabetes With And Without Cardiovascular Disease

Initial Results From EMPRISE Real-world Evidence Study Show Jardiance® Was Associated With Reduced Risk For Hospitalization For Heart Failure Compared With DPP-4 Inhibitors In People With Type 2 Diabetes With And Without Cardiovascular Disease

- Jardiance (empagliflozin) was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Lilly And Dicerna Announce RNAi Licensing And Research Collaboration

Lilly And Dicerna Announce RNAi Licensing And Research Collaboration

- Companies will collaborate on RNAi research for cardio-metabolic, neurodegeneration and pain targets

Eli Lilly Is Just Taking a Normal Pause

Eli Lilly Is Just Taking a Normal Pause

LLY has made a good run this year and now looks like it will correct a bit.

Tariffs and the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/24/18)

Tariffs and the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/24/18)

This is serious: The market is ignoring legitimate, positive earnings, says Jim Cramer, and tariffs and rates are the culprits.

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

Jim Cramer is ready to call the Fed out. And he has your game plan ready for next week.

GoPro, Eli Lilly, HealthEquity: 'Mad Money' Lightning Round

GoPro, Eli Lilly, HealthEquity: 'Mad Money' Lightning Round

Jim Cramer weighs in on GoPro, Eli Lilly, HealthEquity, General Mills, and Marriott International.

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Jim Cramer says it'll be hard for stocks to stabilize until the Fed's stance softens. He's got your game plan for next week.

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Complete Results From First Study In Ongoing Phase 3 Program For Tanezumab Demonstrated Significant Improvement In Pain And Function In Osteoarthritis Patients

Complete Results From First Study In Ongoing Phase 3 Program For Tanezumab Demonstrated Significant Improvement In Pain And Function In Osteoarthritis Patients

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients...

TheStreet Quant Rating: B+ (Buy)